Wegovy 6-Week Weight Loss Results: What the Evidence Actually Shows

Six weeks in: why the dose you're on matters more than the number on the scales

The most common reason people feel their six-week results are underwhelming is that they're still on a starter or near-starter dose. Wegovy's licensed titration schedule works up from 0.25mg through 0.5mg, 1.0mg and 1.7mg before reaching the 2.4mg maintenance dose, with roughly a month at each level. At six weeks, many patients are only just completing their second pen.

That staged approach exists for a clinical reason: pushing the dose too fast drives more nausea, vomiting and other gastrointestinal discomfort. The body needs time to adapt. So if the scales have barely shifted by week six, the honest explanation is often timing, not treatment failure. The medicine hasn't finished arriving yet.

Weight lost at this stage also varies considerably by starting weight, diet changes and individual metabolism. Some people notice a clear reduction in appetite from the first or second week; others feel little change until dose three or four. Both patterns appear in trial data. If you want a sense of how results tend to unfold week by week, our page on Wegovy weight loss results per week breaks down the typical progression alongside this page.

What the trial evidence actually recorded at six weeks

The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and reported an average body-weight reduction of around 15% at the 2.4mg maintenance dose. The trial didn't report a discrete six-week figure, because six weeks sits squarely in the dose-escalation window where results are still accumulating.

What the trial does show is the trajectory: weight loss is gradual through the titration phase and accelerates after participants reach and stay on maintenance dosing. The curve is not flat early and steep later (it's a continuous slope) but the steepest part happens well after week six. For context, the week-five results picture is similarly early-stage.

Expecting the full 15% average at six weeks misreads the trial's shape. A more realistic frame: six weeks of consistent treatment with good tolerability is itself a positive signal that the titration plan is working. That matters more at this stage than any particular number.

The NHS's guidance on weight-management injections reinforces this, noting that prescribers review response after six months on the maintenance dose (not after six weeks) before making any decision about continuing treatment. You can read that NHS England guidance on weight-management injections in full.

Factors that shape your personal six-week result

No two people's week-six picture looks the same, and several factors push results higher or lower than the trial average at this point.

Diet quality sits at the top. Wegovy reduces appetite (most people find they eat noticeably less) but the calorie reduction still depends partly on food choices. Protein adequacy matters here: patients who get enough protein tend to preserve more lean mass as they lose weight, which affects both how they feel and what the scales record. Hydration and fibre intake affect how well the GI side effects are tolerated, and tolerability directly affects whether someone can stick to the titration plan.

Physical activity contributes, but probably less dramatically than many expect in week six. The medicine's primary action is appetite and satiety; activity shapes body composition over time. Strength work becomes more relevant as treatment progresses.

Starting weight affects absolute numbers too. Someone starting at 130kg losing 2% of body weight loses 2.6kg; someone starting at 90kg losing 2% loses 1.8kg. The percentage is the more comparable metric across individuals, and even a 2% reduction at six weeks is within the realistic early range.

Sleep, stress and certain medications can influence results as well. If something feels off, or the side effects at your current dose are genuinely difficult to manage, these are conversations for your prescriber, not things to push through alone. Our clinical team reviews these questions regularly.

Deciding what to do at the six-week mark

Week six is essentially a check-in point. The decision the reader is actually facing is: stay the course, adjust something, or get support?

Stay the course is usually right if appetite has reduced, side effects are manageable and you're progressing through the dose schedule as planned. Loss of even one or two kilograms alongside a real reduction in hunger is the treatment working, and our page covering Wegovy weight loss results gives a broader picture of what people typically achieve as the doses increase. The bigger results come later, at the dose levels reached after the titration phase.

Adjusting something is worth considering if side effects are significant enough to affect eating or daily function, or if the titration hasn't gone as planned. A prescriber can slow the escalation schedule, an option built into the licensed approach, not a deviation from it. Slowing the schedule delays maintenance-dose results, but getting there comfortably beats dropping out at week eight.

Getting support is appropriate if you're uncertain about your progress, have new symptoms, or are wondering whether this is the right treatment at all. If you'd like to understand how long Wegovy takes to work across the full titration journey, that guide sets out a realistic timeline from the first dose onward. If you're curious about what those very early days look like for most people, our guide to week 1 Wegovy weight loss explains what typically happens before the dose escalation begins. For questions about the private route to treatment and what clinical review involves, the treatment overview lays that out plainly.

If you haven't yet started and are weighing up whether Wegovy is appropriate for you, checking your eligibility with a prescriber is the right next step. It's a free consultation, reviewed the same day by a real clinician.